GlassScriptPhysician profile
Azaliia Persits
NPI 1699511824
$622.80
in general payments reported to CMS, 2019-2025
13 companies · $550 in 2025
The $550 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $72.48 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.81 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $142.48 | 2025 | Jakafi, Zynyz, Monjuvi |
| Janssen Biotech, INC. | $87.63 | 2025 | Tecvayli, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $72.64 | 2024-2025 | |
| Glaxosmithkline, LLC. | $54.88 | 2025 | Ojjaara |
| Merck Sharp & Dohme LLC | $47.50 | 2024-2025 | Welireg, Keytruda, Keytruda Qlex |
| Agios Pharmaceuticals, INC. | $41.93 | 2025 | Pyrukynd |
| Shield Therapeutics INC | $30.48 | 2025 | |
| Celgene Corporation | $29.24 | 2025 | Reblozyl |
| Pfizer INC. | $28.31 | 2025 | |
| Deciphera Pharmaceuticals INC. | $27.16 | 2025 | Tgct, Qinlock |
| Jazz Pharmaceuticals INC. | $25.30 | 2024 | |
| Abbvie INC. | $19.60 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.65 | 2025 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azaliia Persits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.